Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13550089 | 0.78 | HTT (0.37) | RAPGEF4KMT2AMEN1HTTSOS1 | |
| SCHEMBL13550095 | 0.78 | RAPGEF4 (0.42) | RAPGEF4KMT2AHTTPDK2NOTUM | |
| SCHEMBL22454710 | 0.77 | RAPGEF4 (0.34) | RAPGEF4HTTPDK2NOTUM | |
| SCHEMBL29676064 | 0.75 | CYP3A4 (0.41) | NOTUMALDH1A1 | |
| SCHEMBL13550069 | 0.75 | NT5E (0.33) | RAPGEF4NT5ENOTUM | |
| SCHEMBL23043288 | 0.75 | HSD17B10 (0.41) | SOS1NOTUMALDH1A1 | |
| SCHEMBL30034058 | 0.75 | HSD17B10 (0.41) | SOS1NOTUMALDH1A1 | |
| SCHEMBL25417114 | 0.75 | CYP3A4 (0.41) | NOTUMALDH1A1 | |
| SCHEMBL24634001 | 0.75 | NMT1 (0.38) | NT5ENOTUM | |
| SCHEMBL31235132 | 0.75 | SOS1 (0.33) | SOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239788-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | KRAS, NRAS, HRAS | RAPGEF4 121/4885KMT2A 1154/4885MEN1 538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.